🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Second Hospital of Jilin University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Second Hospital of Jilin University as lead sponsor. Synced 26 Sep 2026
4Current trials
0Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Second Hospital of Jilin University is the lead sponsor of 4 current clinical trials in our China register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Observational. The most-studied condition is Coronary Artery Disease.

ClinicalTrials.gov trials by status

  • Not yet open250%
  • Active, closed250%

Trials by phase

  • Observational250%
  • Not applicable250%
01

Clinical trials sponsored by Second Hospital of Jilin University

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study
NCT07650487 · ClinicalTrials.gov ↗ · Myocardial Injury, Coronary Artery Disease
Observational Not yet open 2026-07 China
Total Arterial vs. Mixed Grafting in Left Coronary CABG
NCT07057713 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Coronary Artery Bypass Grafting, Arterial Graft
Not applicable Not yet open 2026-08 China
A Study on a New Indicator for Assessing the Difficulty of Colonoscopy Insertion and Its Related Factors
NCT07228715 · ClinicalTrials.gov ↗ · the Difficulty of Colonoscopy Insertion
Observational Active, closed 2025-06 China
Comparison of RIMA-SVG and Ao-SVG Techniques in Coronary Artery Bypass Grafting
NCT06787651 · ClinicalTrials.gov ↗ · Coronary Artery Bypass Grafting, Coronary Artery Disease, Saphenous Vein
Not applicable Active, closed 2025-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Second Hospital of Jilin University trials

7 conditions
Coronary Artery Disease3Coronary Artery Bypass Grafting2Graft Patency2the Difficulty of Colonoscopy Insertion1Saphenous Vein1Myocardial Injury1Arterial Graft1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China40

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Coronary Artery Disease

SponsorTrials
China National Center for Cardiovascular Diseases12
Nanjing First Hospital, Nanjing Medical University10
Second Affiliated Hospital, Zhejiang University, School of Medicine8
Shanghai Zhongshan Hospital7
Xijing Hospital6
Seung-Jung Park3
National University of Ireland, Galway, Ireland2
Philips Clinical & Medical Affairs Global2
Biosensors Europe2
M.A. Med Alliance2

Sponsors with the most current trials registered for this condition.

05

Questions about Second Hospital of Jilin University trials

How many clinical trials does Second Hospital of Jilin University sponsor?

Second Hospital of Jilin University is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Second Hospital of Jilin University trials recruiting?

Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.